Responses
Late-breaking abstracts
Clinical trials completed
791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)
Compose a Response to This Article
Other responses
No responses have been published for this article.
